In addition to the leads, BCAA catabolism agents such as the inhibitors of branched-chain α-ketoacid dehydrogenase kinase (BDKDK), BT2 and sodium phenylbutyrate (NaPB), can also be exploited therapeutically to ameliorate CKD. Here, BCKDK is linked to chronic kidney disease.